Alessandra Tedeschi

13.0k total citations · 5 hit papers
212 papers, 4.5k citations indexed

About

Alessandra Tedeschi is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Alessandra Tedeschi has authored 212 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Genetics, 121 papers in Pathology and Forensic Medicine and 63 papers in Hematology. Recurrent topics in Alessandra Tedeschi's work include Chronic Lymphocytic Leukemia Research (177 papers), Lymphoma Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (49 papers). Alessandra Tedeschi is often cited by papers focused on Chronic Lymphocytic Leukemia Research (177 papers), Lymphoma Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (49 papers). Alessandra Tedeschi collaborates with scholars based in Italy, United States and Australia. Alessandra Tedeschi's co-authors include Marco Montillo, Carol Moreno, Enrica Morra, Constantine S. Tam, Roberto S. Accolla, Francesca Ricci, Paolo Ghia, Meletios Α. Dimopoulos, Roberto Cairoli and Efstathios Kastritis and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Alessandra Tedeschi

197 papers receiving 4.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

2018 380 citations Carol Moreno, Alessandra Tedeschi et al. profile →
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

2019 312 citations Jan A. Burger, Paul M. Barr et al. Leukemia profile →
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

2022 146 citations Paul M. Barr, Carolyn Owen et al. Blood Advances profile →
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025 21 citations Jennifer R. Brown, John F. Seymour et al. profile →

Peers

Countries citing papers authored by Alessandra Tedeschi

Since Specialization

Citations

This map shows the geographic impact of Alessandra Tedeschi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandra Tedeschi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandra Tedeschi more than expected).

Fields of papers citing papers by Alessandra Tedeschi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandra Tedeschi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandra Tedeschi. The network helps show where Alessandra Tedeschi may publish in the future.

Co-authorship network of co-authors of Alessandra Tedeschi

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandra Tedeschi. A scholar is included among the top collaborators of Alessandra Tedeschi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandra Tedeschi. Alessandra Tedeschi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL 2025 ·Blood ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, (unknown), Cathy Zhou, (unknown), Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	5
2	Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results 2025 ·Journal of Clinical Oncology ·Mazyar Shadman, Talha Munir, Shuo Ma, Masa Lasica, Monica Tani, Tadeusz Robak, Ian W. Flinn, Jennifer R. Brown, Paolo Ghia, Emmanuelle Ferrant, Constantine S. Tam, Wojciech Janowski, Wojciech Jurczak, Linlin Xu, Tian Tian, Marcus Lefebure, (unknown), Jamie Hirata, Alessandra Tedeschi	3
3	Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib 2025 ·Leukemia ·Alessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, Giorgio Minotti	0
4	Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA). 2024 ·Journal of Clinical Oncology ·Mazyar Shadman, Jennifer R. Brown, (unknown), (unknown), Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan O’Brien, Alessandra Tedeschi, Constantine S. Tam	1
5	CLL-076 Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers Patten, Sebastian Grosicki, Helen O. McCarthy, Fritz Offner, Edith Szafer‐Glusman, Cathy Zhou, Anita Szőke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps	4
6	Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia 2024 ·Leukemia & lymphoma ·Marina Deodato, Anna Maria Frustaci, (unknown), (unknown), Carlo Gambacorti‐Passerini, Roberto Cairoli, Marco Montillo, Alessandra Tedeschi	1
7	CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·William G. Wierda, Ryan Jacobs, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan O’Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis Carney, (unknown), Javier de la Serna, Edith Szafer‐Glusman, Cathy Zhou, (unknown), James P. Dean, Paolo Ghia, Constantine S. Tam	0
8	Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus‐based position paper from an ad hoc expert panel 2023 ·Hematological Oncology ·Pier Luigi Zinzani, Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni, Francesco Zaja, Giovanni Barosi	2
9	FIXED‐DURATION IBRUTINIB + VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM THE FD COHORT OF THE PHASE 2 CAPTIVATE STUDY 2023 ·Hematological Oncology ·Paolo Ghia, John N. Allan, Tanya Siddiqi, William G. Wierda, Constantine S. Tam, Carol Moreno, Alessandra Tedeschi, Edith Szafer‐Glusman, Cathy Zhou, (unknown), James P. Dean, Andreı̈ Szöke, Paul M. Barr	1
10	Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts 2022 ·Clinical Cancer Research ·Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia, Daniele Vallisa, Ryan Jacobs, Susan O’Brien, Andrew Grigg, Patricia Walker, Cathy Zhou, Joi Ninomoto, (unknown), Constantine S. Tam	6
11	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia breakdown → 2022 ·Blood Advances ·Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia	146
12	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort breakdown → 2022 ·Blood ·Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, (unknown), Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer‐Glusman, (unknown), Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia	124
13	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial 2021 ·Clinical Cancer Research ·Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios Α. Dimopoulos	27
14	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up 2020 ·Blood ·Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Muñoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Atwal, Yiling Yu, William Novotny, Eric Holmgren, (unknown), James Hilger, Jane Huang, Constantine S. Tam	73
15	PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) 2019 ·HemaSphere ·Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	3
16	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 2019 ·Blood ·Constantine S. Tam, Tanya Siddiqi, John N. Allan, Thomas J. Kipps, Ian W. Flinn, Bryone J. Kuss, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Ryan Jacobs, Xavier C. Badoux, Paolo Ghia, Juthamas Sukbuntherng, Ahmed Hamed Salem, (unknown), Karl Eckert, Cathy Zhou, Joi Ninomoto, Danelle F. James, William G. Wierda	31
17	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Susan O’Brien, Peter Hillmen, Steven Coutré, Paul M. Barr, Graeme Fraser, Alessandra Tedeschi, Jan A. Burger, Marie‐Sarah Dilhuydy, Georg Heß, Carol Moreno, Paula Cramer, Emily Liu, Stephen Chang, Jessica Vermeulen, Lori Styles, Angela Howes, Danelle F. James, (unknown), Thorsten Graef, (unknown)	63
18	Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM) 2016 ·Journal of the American Geriatrics Society ·(unknown), Thomas J. Kipps, Tadeusz Robak, Alessandra Tedeschi, Carolyn Owen, Paolo Ghia, Peter Hillmen, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, JA Burger	1
19	Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia 2006 ·Journal of Clinical Oncology ·Marco Montillo, Alessandra Tedeschi, Sara Miqueleiz, Silvio Veronese, Roberto Cairoli, (unknown), Francesca Ricci, (unknown), Barbara Scarpati, Michela Montagna, Michele Nichelatti, Mario Regazzi, Enrica Morra	111
20	IgE-mediated food allergy. 1987 ·PubMed ·Elide A. Pastorello, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alessandra Tedeschi, Raffaella Ansaloni, C Zanussi	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact